Several approaches to inhibit CD47/SIRPα signaling are currently being tested in cancer, either specifically blocking CD47 or SIRPα with antibody-based or gene knockout approaches, as well as bispecific approaches that block both CD47 and SIRPα [65–68]. Here, SIRPA is linked to cancer.